Lung Cancer Diagnostics Market To Reach $7.26 Billion By 2030

Lung Cancer Diagnostics Market Growth & Trends

The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies. 

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer. 

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.

 Request a free sample copy or view report summary: Lung Cancer Diagnostics Market Report

Lung Cancer Diagnostics Market Report Highlights

• The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.

• EGFR mutation tests dominated the market with a 29.2% market share for 2023. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.

• The hospitals and clinics segment dominated the market in 2023. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.

• North America dominated the global lung cancer diagnostics market in 2023 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.

Lung Cancer Diagnostics Market Segmentation

Grand View Research has segmented the global lung cancer diagnostics market on the basis of type, test, end use, and region:

Lung Cancer Diagnostics Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Non-small cell lung cancer

• Small cell lung cancer  

Lung Cancer Diagnostics Test Outlook (Revenue, USD Billion, 2018 - 2030)

• CA test

• HER2 test

• ALK test

• Angiogenesis Inhibitors

• EGFR Mutation test

• KRAS Mutation test

Lung Cancer Diagnostics End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals and clinics

• Diagnostic Laboratories

• Others

Lung Cancer Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Kuwait

  • South Africa

List of Key Players of Lung Cancer Diagnostics Market

• F. Hoffmann-La Roche Ltd

• Thermo Fisher Scientific

• Illumina Inc

• Agilent Technologies

• Qiagen

• Abbott

• Bio-Rad

• Neogenomics Laboratories

• bioMérieux

• Myriad Genetics, Inc